Arak University of Medical Sciences is an Iranian medical school located in Arak, Iran. This university is the main health care provider in Markazi province and one of the biggest universities central of Iran. The university was established by efforts of the director of regional organizations for Health in Markazi province and Majlis representative of Arak and authorities of Ministry of Health, Treatment and Medical Education. After getting the required permissions for the founding of Arak School of Medicine in 1987, and in February 1988 School of Medical Sciences commenced its activities with gathering the school of medicine and college of nursing and midwifery together with accepting 60 students in the medical field and was separated and did its activity independently in 1988.In 1990, The University was converted to "University of Medical Sciences".In 1994 with the inclusion of regional organizations for Health in the University of Medical Sciences, this university was named the University of Medical Sciences and Health Services, Markazi Province, and it took responsibility for offering health services in province.
As there has not been a comprehensive systematic review on the prevalence of contact dermatitis in dental professionals, the aim of this study is to determine the global prevalence of occupational contact dermatitis (OCD) and occupational skin diseases (OSD) in dental professionals. In this meta-analysis, a search in databases including web of sciences, PubMed and Scopus was conducted until June 14, 2024. Google Scholar was examined to find relevant studies. The retrieved articles were screened and the necessary data were extracted from related articles and entered into the analysis. To evaluate the methodological quality of the included studies (risk of bias), the Newcastle–Ottawa Quality Assessment Scale, adapted for cross-sectional and cohort studies was used. In conducting a meta-analysis of articles related to OSD and OCD, heterogeneity and publication bias were observed. The results showed that the prevalence of OCD among dental professionals is 34
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment, with no definitive cure currently available. Neuroinflammation, oxidative stress, and amyloid-beta accumulation play central roles in disease progression. While curcumin shows therapeutic promise, its clinical efficacy is limited due to poor bioavailability. This study investigates the neuroprotective effects of chitosan-curcumin nanoparticles in a streptozotocin (STZ)-induced rat model of AD, focusing on cognitive performance, hippocampal integrity, and molecular markers of neurodegeneration. Sixty male Wistar rats were randomly divided into five groups: control, AD, AD + chitosan, AD + curcumin, and AD + chitosan-curcumin. AD was induced via intraventricular injection of STZ (3 mg/kg). Two weeks’ post-induction, cognitive function was assessed using the Morris water maze (MWM). At the end of the treatment period, oxidative stress parameters, inflammatory cytokines, and gene expression levels (IL-1β, IL-6, IL-10, NRF2, PPARγ, BDNF) were measured via real-time PCR. Data were analyzed using one-way ANOVA with Tukey’s post hoc test (p < 0.05). Rats treated with chitosan-curcumin nanoparticles exhibited significantly improved memory and learning compared to all other groups (p < 0.001). There was a marked downregulation of IL-1β and IL-6, along with increased expression of NRF2, PPARγ, and BDNF (p < 0.05). Histological analysis confirmed reduced neuronal damage and increased neuronal density. Chitosan-curcumin nanoparticles demonstrated potent neuroprotective effects, enhancing cognitive performance, reducing inflammation and oxidative stress, and preserving neuronal structure. These multifaceted effects highlight the therapeutic potential of CS–CUR nanoparticles in targeting the core pathological mechanisms of AD. Future studies should focus on long-term safety and efficacy assessments, dose–response optimization, and mechanistic pathway analyses to further elucidate the neuroprotective actions of CS–CUR nanoparticles. Additionally, translational and clinical investigations are warranted to validate the therapeutic potential of this nanocarrier system for Alzheimer’s disease management.
Abstract Background Peters Plus syndrome (PPS) is an autosomal recessive disorder characterized by a combination of anterior segment abnormalities of the eye, disproportionate short stature, distinctive facial features, and developmental delay caused by a B3GLCT gene mutation. Case presentation A 12-month-old boy who was referred for short stature and had a significant decrease in growth index during follow-up was treated with growth hormone (GH) for five years from the age of 2 years due to growth hormone deficiency and genetic findings consistent with PPS, which resulted in a significant improvement in his growth velocity. Additionally, the patient presented posterior segment ocular findings, including bilateral retinal atrophy. Conclusions Growth hormone therapy was an effective option with favorable safety profile for increasing growth velocity and improving height in our PPS patient studied. Chorioretinal findings, including bilateral retinal atrophy and retinal detachment may develop because of severe myopia.
Multiple myeloma (MM) is a complex hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. Despite advances in therapy, resistance remains a significant obstacle to curing the disease. Long non-coding RNAs (lncRNAs), a broad family of regulatory RNA molecules, have recently been recognized as important players in MM biology, influencing disease progression and treatment response. This review explores current insights into the diverse roles of lncRNAs in MM, focusing on their involvement in key molecular processes, including miRNA sponging, epigenetic regulation, apoptosis, and interactions with signaling pathways such as PI3K/Akt and STAT3. Additionally, the review evaluates emerging treatment strategies targeting lncRNAs, including RNA-based therapeutics, CRISPR/Cas9 technology, and exosome-mediated delivery systems, assessing their potential to overcome drug resistance and improve clinical outcomes. By integrating molecular research with clinical implications, this review emphasizes the promise of lncRNAs as biomarkers and therapeutic targets in MM and offers a framework for future research and development.
Psilocybin may effectively treat psychological distress in cancer patients. A meta-analysis assessed its safety and effectiveness in this context. A comprehensive search across six databases (Scopus, PsycINFO, PubMed, Cochrane, CINAHL Complete, and Web of Science) was conducted to identify studies on psilocybin’s effects on mental health in cancer patients up to November 2024. Both randomized and non-randomized trials were included, assessing anxiety, depression, and other mental outcomes at short-term (2–5 weeks) and long-term (6 months) follow-ups. Study quality was assessed using Cochrane tools, and statistical analyses were performed with Stata version 17. In randomized controlled trials (RCTs), psilocybin significantly reduced depressive symptoms, with the Beck Depression Inventory (BDI) (standardized mean difference [SMD] = − 2.87, 95
